Sweden's Dynavox Q2 revenue misses estimates on US market issues
Sweden's Dynavox Q2 revenue misses estimates on US market issues
Overview
Sweden assistive communication firm's Q2 revenue grew 11% but missed analyst expectations
Q2 operating profit more than doubled, with gross margin rising to 70%
Company completed acquisition of SR Labs Healthcare in Italy during the quarter
Outlook
Dynavox maintains long-term targets of 20% avg annual revenue growth (currency adjusted) and EBIT margin above 15%
Company says underlying market demand remains strong, but macroeconomic and geopolitical volatility persists
Dynavox expects to mitigate rising component costs through increased reimbursement levels and other measures
Result Drivers
BROAD-BASED DEMAND - Co said revenue growth was broad-based across geographies and product groups, reflecting continued demand for assistive communication solutions
OPERATING PLATFORM - Co attributed higher operating profit to benefits from a more streamlined and digitized operating platform, with non-recurring costs largely behind
NORTH AMERICA ORDER TIMING - Co said North America revenue benefited partly from delayed Q1 orders, though this was offset by more drawn-out prescription processes
Company press release: ID:nWkr5VFgsj
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Miss | SEK 670 mln | SEK 680.78 mln (4 Analysts) |
Q2 Gross Margin |
| 70.00% |
|
Q2 Operating Margin |
| 15.70% |
|
Q2 Operating Profit |
| SEK 105 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the integrated hardware & software peer group is "buy"
Wall Street's median 12-month price target for Dynavox Group AB is SEK111.00, about 70.1% above its July 21 closing price of SEK65.25
The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 25 three months ago
Reuters Recommended Reads
July 21 - Sweden's Asker Healthcare Q2 profit jumps on increased scale
July 22 - Sweden's Hansa Biopharma Q2 revenue dips
July 20 - Sweden's Devyser Diagnostics Q2 sales fall on distributor inventory adjustment
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)